-
1
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl JMed 2015; 372(4): 320-330.
-
(2015)
N Engl JMed
, vol.372
, Issue.4
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
-
2
-
-
84931083080
-
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
-
Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4): 375-384.
-
(2015)
Lancet Oncol
, vol.16
, Issue.4
, pp. 375-384
-
-
Weber, J.S.1
D'Angelo, S.P.2
Minor, D.3
-
3
-
-
84938205998
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
-
Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16(8): 908-918.
-
(2015)
Lancet Oncol
, vol.16
, Issue.8
, pp. 908-918
-
-
Ribas, A.1
Puzanov, I.2
Dummer, R.3
-
4
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517-2526.
-
(2011)
N Engl J Med
, vol.364
, Issue.26
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
-
5
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1): 23-34.
-
(2015)
N Engl J Med
, vol.373
, Issue.1
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
-
6
-
-
84933678156
-
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
-
Eggermont AMM, Chiarion-Sileni V, Grob J-J et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16(5): 522-530.
-
(2015)
Lancet Oncol
, vol.16
, Issue.5
, pp. 522-530
-
-
Eggermont, A.M.M.1
Chiarion-Sileni, V.2
Grob, J.-J.3
-
7
-
-
84929481481
-
Pembrolizumab versus ipilimumab in advanced melanoma
-
Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26): 2521-2532.
-
(2015)
N Engl J Med
, vol.372
, Issue.26
, pp. 2521-2532
-
-
Robert, C.1
Schachter, J.2
Long, G.V.3
-
8
-
-
84872339660
-
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
-
Voskens CJ, Goldinger SM, Loquai C et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8(1): e53745.
-
(2013)
PLoS One
, vol.8
, Issue.1
-
-
Voskens, C.J.1
Goldinger, S.M.2
Loquai, C.3
-
9
-
-
84964389238
-
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
-
Zimmer L, Goldinger SM, Hofmann L et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 210-225.
-
(2016)
Eur J Cancer
, vol.60
, pp. 210-225
-
-
Zimmer, L.1
Goldinger, S.M.2
Hofmann, L.3
-
10
-
-
84976585919
-
-
(1 July 2016, date last accessed)
-
Yervoy-Summary of Product Characteristics. http://www.medicines. org.uk/emc/medicine/24779 (1 July 2016, date last accessed).
-
Yervoy-Summary of Product Characteristics
-
-
-
11
-
-
77952118055
-
-
(1 July 2016, date last accessed)
-
Opdivo-Summary of Product Characteristics. https://www.medicines. org.uk/emc/medicine/30476 (1 July 2016, date last accessed).
-
Opdivo-Summary of Product Characteristics
-
-
-
12
-
-
77952118055
-
-
(1 July 2016, date last accessed)
-
Keytruda-Summary of Product Characteristics. https://www.medicines. org.uk/emc/medicine/30602 (1 July 2016, date last accessed).
-
Keytruda-Summary of Product Characteristics
-
-
-
15
-
-
84883053806
-
Multifocal radiculoneuropathy during ipilimumab treatment of melanoma
-
Manousakis G, Koch J, Sommerville RB et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve 2013; 48(3): 440-444.
-
(2013)
Muscle Nerve
, vol.48
, Issue.3
, pp. 440-444
-
-
Manousakis, G.1
Koch, J.2
Sommerville, R.B.3
-
16
-
-
84873821509
-
PD-1 is a novel regulator of human B-cell activation
-
Thibult M-L, Mamessier E, Gertner-Dardenne J et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol 2013; 25(2): 129-137.
-
(2013)
Int Immunol
, vol.25
, Issue.2
, pp. 129-137
-
-
Thibult, M.-L.1
Mamessier, E.2
Gertner-Dardenne, J.3
-
17
-
-
84918507355
-
The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells
-
Sage PT, Paterson AM, Lovitch SB, Sharpe AH. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 2014; 41(6): 1026-1039.
-
(2014)
Immunity
, vol.41
, Issue.6
, pp. 1026-1039
-
-
Sage, P.T.1
Paterson, A.M.2
Lovitch, S.B.3
Sharpe, A.H.4
|